• News

"BRAVO 3: Choice of Vascular Closure Device in TAVR Matters" - Erik Swain

  • Healio: Cardiology Today
  • New York, NY
  • (May 22, 2019)

In a comparison of two vascular closure devices used in transfemoral transcatheter aortic valve replacement procedures, the Perclose ProGlide device was associated with lower rates of vascular complications and acute kidney injury compared with Prostar XL device, according to new data from the BRAVO 3 trial. In a post hoc analysis of BRAVO 3 presented at the Society for Cardiovascular Angiography and Interventions Scientific Session, David Power, MBBCh, an internal medicine resident at the Icahn School of Medicine at Mount Sinai, and colleagues evaluated the 746 patients who were treated with the two devices. “These two devices are still commonly used, and this study may tip the balance toward use of the ProGlide device,” said Dr. Power.

— David Power, MBBCh, Resident, Internal Medicine, Icahn School of Medicine at Mount Sinai

Learn more